drugset / Trial / NCT00884533
QTc Study of Rosi XR in Healthy Volunteers
RandomizedParallel-groupDouble-blindTreatment
Summary
This study is a randomised double blind, parallel group, and will evaluate the effects of repeat oral doses of RSG- XR for 21 days on the QTc interval compared to placebo in a population of healthy adult males and females.
Timeline
- Start
- 2009-06
- Primary completion
- 2009-08
- Completion
- 2009-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Moxifloxacin | Small molecule | 400 mg | Oral |
| Subject | Rosiglitazone | Small molecule | 8 mg | Oral |